Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Âeftilagimod alpha' or Âefti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
IPO Year:
Exchange: NASDAQ
Website: immutep.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/17/2024 | $10.00 | Overweight | CapitalOne |
8/3/2023 | $7.00 | Outperform | Robert W. Baird |
8/3/2021 | $8.30 | Buy | Ladenburg Thalmann |
7/16/2021 | $8.00 | Buy | Maxim Group |
6-K - IMMUTEP Ltd (0001506184) (Filer)
6-K - IMMUTEP Ltd (0001506184) (Filer)
6-K - IMMUTEP Ltd (0001506184) (Filer)
6-K - IMMUTEP Ltd (0001506184) (Filer)
6-K - IMMUTEP Ltd (0001506184) (Filer)
6-K - IMMUTEP Ltd (0001506184) (Filer)
6-K - IMMUTEP Ltd (0001506184) (Filer)
6-K - IMMUTEP Ltd (0001506184) (Filer)
6-K - IMMUTEP Ltd (0001506184) (Filer)
6-K - IMMUTEP Ltd (0001506184) (Filer)
Media Release Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with low PD-L1 expression (TPS 1-49%), and has not been reached in patients with high PD-L1 expression (TPS >50%), exceeding expectationsPromising Overall Survival, Overall Response Rate, Progression Free Survival, and Duration of Response visible across all PD-L1 subgroups (TPS <1%, ≥1%, 1-49%, and ≥50%), differentiates efti in combination with KEYTRUDA® from other chemotherapy-free immuno-oncology combinations in non-small cell lung cancerExceptional durability and quality of responses exhibited through ove
Media Release New updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Saturday, October 21st, at 9:05 CESTImmutep to host webcast to discuss ESMO 2023 clinical data on Monday, October 23rd, at 8AM AEDT (Sunday, October 22nd, at 5PM ET) SYDNEY, AUSTRALIA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the publication of abstracts with data from the TACTI-002 and INSIGHT-003 trials in 1st line non-small cell lung cancer (1L NSCLC) at t
SC 13G/A - IMMUTEP Ltd (0001506184) (Subject)
SC 13G/A - IMMUTEP Ltd (0001506184) (Subject)
SC 13G - IMMUTEP Ltd (0001506184) (Subject)
SC 13G/A - IMMUTEP Ltd (0001506184) (Subject)
Media Release Oral presentation will detail results from the randomized TACTI-003 Phase IIb trial in first line head & neck squamous cell carcinoma patients with any PD-L1 expression (CPS >1) SYDNEY, AUSTRALIA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces a late-breaking abstract has been accepted and selected as a Proffered Paper oral presentation at the 2024 European Society for Medical Oncology (ESMO) Congress, taking place September 13-17 in Barcelona, Spain. The oral presentation will detail resu
Media Release IMP761 is designed to enhance the "brake" function of LAG-3 on T cells to restore balance to the immune system and address the underlying cause of many autoimmune diseasesSafety data from this first-in-human study anticipated by year-end and pharmacokinetics and pharmacodynamics data in first half CY2025 SYDNEY, AUSTRALIA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the first participant has been successfully dosed in the first-in-human Phase I trial of IMP761. This first-in-class a
SYDNEY, AUSTRALIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will present at the following investor conferences: Canaccord Genuity 44th Annual Growth ConferenceLocation:InterContinental Boston Hotel, Boston, MADate: Wednesday, 14 August 2024 Time: 08:30am – 8:55am ET Baird 2024 Global Healthcare ConferenceLocation:InterContinental NY Barclay, New York, NYDate: Tuesday, 10 September 2024Time:01:25pm – 1:55pm ET A live webcast and replay of the presentati
Media Release Entered into third and most important clinical trial collaboration and supply agreement to date with MSD to evaluate eftilagimod alfa (efti) in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for first-line non-small cell lung cancer in a pivotal Phase III trialContinuing positive clinical data reported from efti: Positive results from TACTI-003 Phase IIb trial in first-line head and neck squamous cell carcinoma with efti in combination with KEYTRUDA®Encouraging efficacy and safety data from AIPAC-003 Phase II/III trial with efti and paclitaxel in metastatic breast cancer presented at ESMO Breast Cancer 2024Novel triple combination of efti with radiotherapy and KEY
Media Release Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancerTACTI-004 registrational trial will enrol ~750 patients regardless of PD-L1 expression in order to address the entire 1L NSCLC market eligible for anti-PD-1 therapy SYDNEY, AUSTRALIA, July 22, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, t
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory clearance from the ethics and competent authority in the Netherlands to initiate the first-in-human Phase I study of IMP761. IMP761 is the world's first therapeutic LAG-3 agonist antibody and as such is uniquely positioned in the treatment landscape for autoimmune diseases. The immune checkpoint LAG-3 has been identified as a promising tar
Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1High complete response rate of 9.7% with three patients showing a disappearance of cancer lesions post treatmentDurability of responses tracks well and over 50% of patients received treatment for at least six monthsCombination continues to have a favourable safety profile with no new safety signals observedBased on encouraging results and high unmet medical need, the path forward will be discussed with regulatory agenciesCompany to host we
Company to Host Webcast on 12th July at 9am AEST (7pm ET, 11 July) SYDNEY, AUSTRALIA, July 03, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces details for an upcoming oral presentation at the European Society for Medical Oncology (ESMO) Virtual Plenary session on July 11, 2024, featuring new clinical data in patients with negative PD-L1 expression (Cohort B) in the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial, and a webcast to discuss these clinical results. ESMO Virtual Plenaries are monthly presentations of the la
Media Release SYDNEY, AUSTRALIA, June 25, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces a License Agreement with Cardiff University granting the Company exclusive rights to develop and commercialise anti-LAG-3 small molecules. A number of promising compounds that block LAG-3, an immune checkpoint known to reduce the immune system's response to fight cancer, have been identified under Immutep's collaboration with the world-leading scientists at Cardiff University. Led by Professor Andrew Godkin of Cardiff Univer
Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 ((ASX: IMM, NASDAQ:IMMP) (Immutep or the Company) is pleased to announce the successful completion of its institutional placement (Placement) and the institutional component (Institutional Entitlement Offer) of its 1 for 16 pro rata accelerated non-renounceable entitlement offer (Entitlement Offer and, together with the Placement, the Offer) of new fully paid ordinary shares in Immutep (New Shares). The Placement and Institutional Entitlement Offer (together, the Institutional Offer) closed on 4 June 2024. The Institutional Offer had strong support from institutional investors, with a take-up rate from el
CapitalOne initiated coverage of Immutep with a rating of Overweight and set a new price target of $10.00
Robert W. Baird initiated coverage of Immutep with a rating of Outperform and set a new price target of $7.00
Ladenburg Thalmann initiated coverage of Immutep with a rating of Buy and set a new price target of $8.30
Maxim Group resumed coverage of Immutep with a rating of Buy and set a new price target of $8.00
Alliance Global Partners reiterated coverage of Immutep with a rating of Buy and set a new price target of $6.00 from $5.00 previously
Media Release Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address the underlying cause of autoimmune diseasesCHDR will utilize its unique challenge model that enables insights into IMP761's pharmacological activity early in clinical developmentTrial expected to begin mid-CY2024 SYDNEY, AUSTRALIA, April 18, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has entered into an agreem
Media Release Appointment of Charles River Laboratories ("Charles River") to run Immutep's preclinical toxicology study evaluating the safety and toxicity of IMP761Forms a key step prior to first-in-human trials for this first-in-class LAG-3 agonist antibody designed to treat the underlying cause of multiple autoimmune diseasesCharles River is a highly respected, global provider of drug discovery and non-clinical development solutions operating more than 110 sites across more than 20 countries SYDNEY, AUSTRALIA, May 29, 2023 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LA
Media Release Initiation of integrated Phase II/III AIPAC-003 trial evaluating eftilagimod alpha (efti) and paclitaxel in HER2-neg/low metastatic breast cancer and triple-negative breast cancerPositive final data reported from patients with 2nd line non-small cell lung cancer refractory to anti-PD-(L)1 therapies, including Overall Survival rate of 39% at 21 monthsRandomised TACTI-003 Phase IIb trial has reached 75% enrolment subsequent to quarter end and top line results anticipated in H2 of CY2023Expansion of INSIGHT-003 evaluating triple combination of efti, pembrolizumab and chemotherapy post encouraging initial safety and efficacy in 1st line non-small cell lung cancerSolid cash pos
Media Release SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces that Florian D. Vogl, M.D., Ph.D., MSc, has been appointed as Chief Medical Officer (CMO) with effect from 1 May 2023. Dr. Vogl brings to Immutep over a decade of experience in the biopharmaceutical industry with extensive clinical development expertise in the field of oncology. Most recently, he was CMO of Cellestia Biotech where he focused on delivering new treatments to patients with cancer and autoimmune disorders that had limited therapeutic opti
SYDNEY, AUSTRALIA, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the appointment of its Chief Scientific Officer and Chief Medical Officer, Professor Frédéric Triebel, M.D. Ph.D. as Executive Director. Prof. Triebel will join the Immutep Board with immediate effect. Prof. Triebel pioneered the recently validated LAG-3 field of immuno-oncology, having discovered the LAG-3 gene, its functions and medical usefulness while working at Institut Gustave Roussy (IGR), a large cancer centre in Paris.
SYDNEY, AUSTRALIA, May 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, announced today the appointment of four new members to the Company's Clinical Advisory Board (CAB). The CAB serves as a strategic resource to Immutep as the Company continues to advance its pipeline of LAG-3 programs, including combination therapy programs for lead product candidate eftilagimod alpha ("efti" or "IMP321"). Immutep CSO & CMO, Dr. Frederic Triebel, commented: "We are privileged to have a group of leading oncologists on our Clinical Adv
AIPAC reaches ~72% of events and TACTI-002 recruitment is progressing wellNew data from TACTI-002 and INSIGHT-004 to be reported at ASCO in June 2021TACTI-003 clinical trial design enables evaluation of efti in 1st line recurrent or metastatic HNSCC patients to better understand its effect in combination with pembrolizumabRobust financial position with cash runway into calendar year 2023, beyond several significant data read-outs Sydney, AUSTRALIA, May 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, provides an update on
Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancerTACTI-004 registrational trial will enrol ~750 patients regardless of PD-L1 expression in order to address the entire 1L NSCLC market eligible for anti-PD-1 therapySYDNEY, AUSTRALIA, July 22, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that
Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory clearance from the ethics and competent authority in the Netherlands to initiate the first-in-human Phase I study of IMP761.IMP761 is the world's first therapeutic LAG-3 agonist antibody and as such is uniquely positioned in the treatment landscape for autoimmune diseases. The immune checkpoint LAG-3 has been identified as a promising target for agonist immu
Shares of ASP Isotopes Inc. (NASDAQ:ASPI) fell during Friday's session after the company announced pricing of a $30 million public offering of 12 million shares at $2.50 per share. ASP Isotopes shares fell 9.2% to $3.2308 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Vicinity Motor Corp. (NASDAQ:VEV) shares jumped 133.2% to $0.7910 after the company announced CARB certification for the VMC 1200 class 3 electric truck. Qualigen Therapeutics, Inc. (NASDAQ:QLGN) shares rose 110% to $0.4335. TOYO Co., Ltd (NASDAQ:TOYO) climbed 63.4% to $2.5322. Nisun International Enterprise Development Group Co., Ltd (NASDAQ:NISN) jumped 58% to $9.52 foll
ZAPP: 40% | Zapp Electric Vehicles shares are trading higher after the company announced that it entered into a new standby equity purchase agreement with an affiliate of Yorkville Advisors Global to start production and the commercial rollout of the i300 electric urban motorcycle in India. IMMP: 68% | Immutep shares are trading higher after the company announced results from Cohort B of the TACTI-003 Phase IIb trial evaluating eftilagimod alfa in combination with MSD's anti-PD-1 therapy KEYTRUDA as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression. FAST: 6% | Fastenal shares are trading higher following better-than-
Friday, Immutep Limited (NASDAQ:IMMP) released results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase 2b trial of eftilagimod alfa (efti) in combination with Merck & Co Inc (NYSE:MRK) Keytruda (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression. The updated efficacy and safety data was presented at the ESMO Virtual Plenary session. Related: Cancer Focused Immutep’s Stock Soars On Tuesday – Here’s Why. The investigational immuno-oncology (IO) combination utilizing efti and Keytruda achieved an objective response rate (ORR) of 35.5% (11 of 31 evaluable patients) and a disease control ra
Shares of Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter sales and issued guidance. Ericsson reported a second-quarter loss of 31 cents per share, compared to year-ago earnings of 7 cents per share. The company reported quarterly sales of $5.59 billion which beat the analyst consensus estimate of $5.36 billion, according to data from Benzinga Pro. Ericsson shares jumped 4.3% to $6.66 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Sentage Holdings Inc. (NASDAQ:SNTG) rose 85.6% to $4.27 in pre-market trading after gaining around 5% on
Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1 High complete response rate of 9.7% with three patients showing a disappearance of cancer lesions post treatment Durability of responses tracks well and over 50% of patients received treatment for at least six months Combination continues to have a favourable safety profile with no new safety signals observed Based on encouraging results and high unmet medical need, the path forward will be discussed with regulatory agencies
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Thursday. Shares of Levi Strauss & Co. (NYSE:LEVI) fell sharply in today’s pre-market trading after the company reported mixed second-quarter financial results and issued FY24 EPS guidance with its midpoint below estimates. Levi Strauss reported quarterly earnings of 16 cents per share which beat the analyst consensus estimate of 11 cents by 45.45%. Quarterly sales came in at $1.44 billion, missing the analyst consensus estimate of $1.45 billion. Levi Strauss shares dipped 16.1% to $19.40 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session.